This month, the Centers for Medicare and Medicaid Services launched the Medicare GLP-1 Bridge, a demonstration program that ...

A study outlined the current landscape of obesity prevention and treatment from a clinical and policy standpoint.

Following the White House’s recent announcement of price reductions and expanded coverage for GLP-1 medications like Wegovy and Zepbound, many patients searching for obesity treatments are about to ...

Obesity is a growing global health crisis, affecting millions of people and increasing the risk of chronic diseases like diabetes, heart disease, and stroke. However, the good news is that obesity is ...

GLP-1 drugs may influence cancer risk by reversing obesity-related metabolic dysfunction and inflammation. Researchers are ...

SAN ANTONIO — The upcoming Obesity Week meeting will feature new clinical trial data for glucagon-like peptide 1 receptor agonist (GLP-1 RA) drugs, along with deep dives into clinical, social, and ...

Obesity care is evolving fast, but experts at ICO 2026 warned that access to treatment, prevention strategies, and policy ...

A new report led by researchers at Pennington Biomedical Research Center underscores the growing potential of precision medicine to transform how obesity is prevented, diagnosed and treated, while ...

Obesity is linked to numerous health complications, including diabetes, cardiovascular disease, and fatty liver disease. In a world where obesity rates continue to climb, researchers are constantly ...

The American Society for Nutrition and The Obesity Society recently announced a partnership that offers opportunities for discounted pricing and will advance clinical practice.According to a press ...

Childhood obesity is a serious health problem that has adverse and long-lasting consequences for individuals, families, and communities. The magnitude of the problem has increased dramatically over ...